|
|
Post by lakers on Jul 27, 2016 1:18:50 GMT -5
|
|
|
|
Post by papanigon on Jul 27, 2016 9:22:26 GMT -5
"we aren't meant to inject insulin subcutaneously either". Very nice...
|
|
|
|
Post by peppy on Jul 27, 2016 11:19:46 GMT -5
A pump hiatus. Using Afrezza. Try it, you will like it.
Data from some studies showed:
•Onset of action within 16 to 21 minutes for Afrezza compared to 45 to 52 minutes for subcutaneous insulin across trials
•Afrezza's duration of action at clinically relevant doses was consistently shorter by 2 to 3 hours
•Afrezza's labeled dose overestimates its effect, meaning patients need better titration to get the appropriate dose
•A 4-unit Afrezza cartridge provides approximately the same insulin exposure as 3.1 units of Humalog.
•Lung tests showed PWDs didn't experience any negative lung effects after three months going up to 24 months
In a session on inhaled insulin by Dr. Stefano del Prato from Italy, he presented data indicating that there is "no clinical significance" in reducing A1C. This doctor was actually saying to a lecture-hall room of medical professionals that Afrezza isn't clinically effective, thereby basically implying that it's not worth prescribing or fighting for patient access to this medicine.
I was stunned.
My words, these physicians need to get off their hga1c assets and go with blood glucose levels.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 27, 2016 11:24:39 GMT -5
coming out of hibernation? it was published june 20 and was discussed already |
|
